An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia
Latest Information Update: 28 Jun 2024
At a glance
- Drugs Acalabrutinib (Primary) ; Navtemadlin (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kartos Therapeutics
- 28 Jun 2024 This Trial has been completed in Italy, according to European Clinical Trials Database record.
- 19 Jun 2024 This Trial has been completed in Portugal, according to European Clinical Trials Database record.
- 03 Sep 2023 This Trial has been completed in Belgium according to European Clinical Trials Database record.